Saturday, October 31, 2020
Samay Shah of Taarak Mehta Ka Ooltah Chashmah NOT attacked by goons, actor says ‘That’s not true’
from IndiaTV Entertainment: Google News Feed https://ift.tt/34J0RxK
Bejoy Nambiar: South producers more willing to take risks, experiment
Jasmin Bhasin's BFF Aly Goni to enter Bigg Boss 14 house soon
from IndiaTV Entertainment: Google News Feed https://ift.tt/3mHPGLP
Sean Connery passes away: Hugh Jackman, Hrithik Roshan, Priyanka Jonas and others pay tribute
from IndiaTV Entertainment: Google News Feed https://ift.tt/2TUL0pL
From Ms to Mrs: Kajal Aggarwal shares UNSEEN photos from wedding with 'soulmate' Gautam Kitchlu
from IndiaTV Entertainment: Google News Feed https://ift.tt/35Pbkak
When Sean Connery, wife Micheline Roquebrune spent their Valentine's Day visiting Taj Mahal in 2007
from IndiaTV Entertainment: Google News Feed https://ift.tt/3jNhz36
Ayushmann Khurrana celebrates '125 years of togetherness' with Tahira on wedding anniversary
from IndiaTV Entertainment: Google News Feed https://ift.tt/2TJoYWS
Daniel Craig on Sean Connery: He is the reason ‘James Bond’ character lasted so long
from IndiaTV Entertainment: Google News Feed https://ift.tt/3kKNgLO
Bigg Boss 14: Salman Khan can't stop smiling as Shehnaaz Gill returns on the show, fans trend #SalNaaz
from IndiaTV Entertainment: Google News Feed https://ift.tt/2JqVaML
Happy Birthday Aishwarya Rai Bachchan: When the blue-eye beauty was crowned Miss World 1994 | VIDEO
from IndiaTV Entertainment: Google News Feed https://ift.tt/3oLoZYw
Anubhav Sinha announces romantic Bhojpuri number after Bambai main ka ba
Loneliness and Social Isolation are Prone to High Blood Pressure and Hypertension in Women
from Top Lifestyle News- News18.com https://ift.tt/3jJjVAi
Bigg Boss 14 PROMO: Salman Khan schools Rahul Vaidya on his 'nepotism' comment | Video
from IndiaTV Entertainment: Google News Feed https://ift.tt/31XOf47
Ira Khan's spooky makeup to Neha Dhupia's daughter turning into a witch, B'wood celebrates Halloween 2020
from IndiaTV Entertainment: Google News Feed https://ift.tt/2TEYAgz
Halloween 2020: How to Make Spooky Halloween Cards to Scare Your Friends
from Top Lifestyle News- News18.com https://ift.tt/3kK1jRV
Actor Bineesh Kodiyeri's membership in AMMA to remain intact
from IndiaTV Entertainment: Google News Feed https://ift.tt/3jHlTRp
Payal Ghosh tests negative for COVID-19
from IndiaTV Entertainment: Google News Feed https://ift.tt/35OX55g
Akshay Kumar, Kiara Advani starrer Laxmmi makers release latest poster with new title
from IndiaTV Entertainment: Google News Feed https://ift.tt/35PyI7t
Friday, October 30, 2020
Sanya Malhotra on why working with Anurag Basu was a different experience
Find the PC that’s just right for you
Selecting the best PC to match your requirement can be intimidating. Let's help you select the right computer that will suit your needs. So, let's first build your profile and check what you're looking for.
Looking for more information on Intel®️ powered PCs? Please visit our retail partners, Flipkart, Amazon, Croma, and Reliance Digital.
This is a partnered content.
from Firstpost Tech Latest News https://ift.tt/34GxTOS
Koena Mitra alleges Twitter is shadow banning her for her opinions
from IndiaTV Entertainment: Google News Feed https://ift.tt/2HQCaqr
Shah Rukh Khan's fans to virtually celebrate his birthday on November 2
from IndiaTV Entertainment: Google News Feed https://ift.tt/34Hd5qr
Kangana Ranaut pays tribute to Sardar Vallabhbhai Patel on 145th birth anniversary: You gave us Akhand Bharat
from IndiaTV Entertainment: Google News Feed https://ift.tt/3oIG7ht
Sonu Sood's hilarious reply to man asking him to arrange a Maldives vacation: Cycle or rickshaw?
from IndiaTV Entertainment: Google News Feed https://ift.tt/2TET2mh
Kanye West gifts wife Kim Kardashian hologram of her late father on birthday
from IndiaTV Entertainment: Google News Feed https://ift.tt/3ebPcuo
From Boosting Sexual Health to Slowing Down Ageing: 5 Health Benefits of Ashwagandha
from Top Lifestyle News- News18.com https://ift.tt/31YJNCe
3 Yoga Asanas That Can Help Open Up the Hips and Improve Flexibility
from Top Lifestyle News- News18.com https://ift.tt/3mEtxOm
What is Bronchitis and How is it Different from Common Cold?
from Top Lifestyle News- News18.com https://ift.tt/3ek79Hm
TRP Race: Saath Nibhaana Saathiya 2 Enters Top 5, Becomes a Competition to Saath Nibhaana Saathiya 1
from Top Lifestyle News- News18.com https://ift.tt/3oK7gR6
Mahesh Bhatt's sister files defamation case against actress Luviena Lodh, demands apology and Rs 90 lakh
from IndiaTV Entertainment: Google News Feed https://ift.tt/3edvrm8
Salman Khan shot for London Dreams hours after his dogs' funeral, Vipul Shah recalls as film clocks 11 years
from IndiaTV Entertainment: Google News Feed https://ift.tt/34KXdn7
Kajal Aggarwal Weds Gautam Kitchlu: Dreamy inside photos from their fairytale wedding
from IndiaTV Entertainment: Google News Feed https://ift.tt/320IUsD
Kubbra Sait gatecrashed Ranveer Singh-Deepika Padukone's wedding 'with an invitation'
Thursday, October 29, 2020
Gilead’s COVID-19 drug remdesivir is mediocre at best – and bound to become a blockbuster
The United States reached a milestone, of sorts, when last week the Food and Drug Administration approved the first treatment for COVID-19.
The drug is called Veklury, although most people know it by its scientific name, remdesivir.
On Wednesday, its manufacturer, Gilead Sciences, said that remdesivir, which has been authorized for emergency use since the spring, had brought in $873 million in revenues so far this year and that it was the company’s second-best-selling drug in the third quarter, behind its HIV drug, Biktarvy.
But the FDA’s decision to grant the drug full approval — which means the company can begin broadly marketing it to doctors and patients — has puzzled several outside experts, who say that it may not deserve the agency’s stamp of approval because it is, at best, a mediocre treatment for COVID-19, the disease caused by the coronavirus. And they have questioned whether Gilead deserves to pocket potential billions from the drug when the federal government has played a significant role in its development.
“This is a troubling approval,” said Dr. Peter B. Bach, director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center. “This is an extremely weak set of trials to support an approval for an antiviral.”
Remdesivir was seen as one of brightest hopes in the dark days of March and April, when doctors had few tools to treat a new disease and families rushed to gain access to the drug in a desperate gambit to save their dying relatives.
More than six months later, enthusiasm has fizzled. One large, government-run trial showed that the drug shortens patients’ recovery times, but the two other studies the FDA used to justify its approval — sponsored by Gilead — did not compare the treatments with a placebo, the gold standard for evaluating a drug. No studies have shown that it significantly lowers death rates.
And just days before the FDA granted approval, a large study sponsored by the World Health Organization found that remdesivir provided no benefit to hospitalized patients.
“I think most people think that because a drug is FDA approved, that means it must work,” said Dr. Aaron S. Kesselheim, a professor of medicine at Harvard Medical School who studies the drug industry. He and other researchers recently found that less than one-third of new drugs approved by the FDA and its European counterpart over the past decade were rated as having a “high therapeutic value” by outside experts.
“I think it’s important to recognize that FDA approval doesn’t guarantee a certain level of benefit — all it says is that there is some benefit,” he said.
On a call with investors Wednesday, Gilead’s chief executive, Daniel O’Day, said remdesivir had a role to play, along with vaccines and other treatments.
“There’s a lot we don’t know about the pandemic, of course, but I think what we do know is that in order to get us all back to normal, this is going to take a variety of approaches,” he said. “We’re proud to be at the front end of this with a very potent antiviral.”
Remdesivir was originally developed as a treatment for Ebola and hepatitis C and is thought to interfere with the reproduction of viruses by jamming itself into new viral genes.
Because it had previously shown promise in animal studies of other coronaviruses, it was almost immediately seen as a possible answer for COVID-19. Gilead rushed emergency doses to China and began ramping up manufacturing.
The drug was initially used on the very sick but has since been found to work better earlier in the course of the disease. It is routinely given as a five-day treatment to people who are hospitalized for COVID-19, including to President Donald Trump when he was infected earlier this month.
Gilead has come under criticism for its efforts to profit from the drug. In March, when there were still fewer than 200,000 cases of COVID-19, the company applied to the FDA to label remdesivir as an orphan drug, a designation that provides tax and other incentives to companies developing products for rare diseases. After a public outcry, it asked the FDA to rescind its application.
Gilead has gotten mixed reviews from outside experts over the price it has set, at $3,120 for a course of treatment for private insurers and $2,340 for government entities.
One outside group that evaluates drug prices, the Institute for Clinical and Economic Review, said Gilead had made a “responsible pricing decision” that was in line with its own determination that $2,800 would be a fair price. However, that praise came with a significant caveat — the price would be fair only if remdesivir ultimately showed that it significantly lowered death rates, a benefit that has not been proven.
Others say the company’s profits are unfair, given how much support it has gotten from the government. Public Citizen, a consumer group, has estimated that the federal government has invested $70 million in remdesivir, and it sponsored the major trial that led to FDA approval — and the only major study that compared it with a placebo.
“Remdesivir should be in the public domain,” said Peter Maybarduk, director of the global access to medicines program at Public Citizen. “Gilead will have remade its modest investment many times over.”
In August, attorneys general from 34 states wrote to federal health officials asking them to exercise so-called march-in rights to alleviate shortages of the drug (which have since been resolved). And in September, 11 state treasurers wrote to the company, asking it to price the drug “more affordably.”
In a statement, Gilead said that its own investments in the drug this year “will exceed $1 billion, primarily due to early investments in the rapid scale up of manufacturing, and we expect to invest significantly more in 2021 as we make additional investments in development and manufacturing around the world.”
The company said that by December, it expected to have produced enough drug to treat 2 million patients and that it was studying an inhaled form of the drug that could expand its use to outpatients.
Last week, Gilead came under new criticism because when remdesivir was approved, the company was awarded a priority review voucher, an incentive that allows it to get expedited review from the agency for a future product or to sell that right to another company. The vouchers, which can sell for about $100 million on the open market, are awarded to companies that develop products — such as ones that address a public health threat like a pandemic — that might not otherwise be profitable.
But remdesivir is already proving to be a significant moneymaker for Gilead.
“The idea behind the priority review vouchers program is that there’s relatively little financial incentives for companies to make drugs for some of these conditions,” said Rachel Sachs, an associate professor of law at Washington University in St. Louis who studies drug policy. “If we think that this drug will be a blockbuster, then the reasons why we created the program would seem to apply with much less force here.”
The FDA’s approval was surprising to some because it came just days after the release of results from the Solidarity trial, a large, global study of more than 11,000 people that found that remdesivir did not reduce deaths.
Both the FDA and Gilead have noted, however, that the Solidarity trial had shortcomings, including that it was not compared with a placebo, as the trial sponsored by the National Institutes of Health was.
Now that Veklury is FDA-approved, Gilead can begin marketing it, including to doctors and hospitals that might be reluctant to use the treatment.
Gilead said it did not plan to run television advertising for Veklury but would deploy a “field team of medical and sales professionals to educate health care professionals across the country.”
It said it also had plans “to develop some direct-to-consumer materials on Veklury, focused on providing information and education for patients and their families.”
Veklury’s future sales are uncertain. On the call with investors, executives said that predicting revenues in the middle of a pandemic is difficult. Around 40% to 50% of hospitalized COVID-19 patients receive the drug — fewer than some industry analysts had expected. But the drug is profitable so far. One Wall Street analyst, Geoffrey Porges of SVB Leerink, said Thursday that the company’s gross margin on sales to the government — the amount it pockets after the cost to produce it — appeared to be about 90%.
In the call with investors, O’Day said that he expected Veklury to ultimately provide a “very good return” on the company’s investment. “We do feel very strongly that Veklury will contribute to our overall sales, being an important source of cash for our business,” he said.
Bach, of Memorial Sloan Kettering, said that as doctors’ knowledge of COVID-19 had evolved, the significance of remdesivir had receded in favor of other options, including dexamethasone, a steroid made by several generic drug companies.
Because the steroid is a cheap, widely available drug whose patent protections have long since expired, there is little incentive for those companies to seek formal approval from the FDA to be able to market the drug for COVID-19.
That gives Gilead a potential marketing advantage, with no other drug company actively competing for sales. But the purpose of an approval is not to grant companies a financial incentive.
“The FDA doesn’t exist to give monetary prizes to drug companies,” Bach said. “The FDA exists to help inform doctors as to what drugs they should give patients in front of them today.”
Katie Thomas. c.2020 The New York Times Company
from Firstpost Tech Latest News https://ift.tt/3jGG4iz
First extraterrestrial cellular service? Nokia chosen by NASA to set up 4G network on the Moon
With competition among Earth's telecoms providers as fierce as ever, equipment maker Nokia announced its expansion into a new market on Monday, winning a deal to install the first cellular network on the Moon.
The Finnish equipment manufacturer said it was selected by NASA to deploy an "ultra-compact, low-power, space-hardened" wireless 4G network on the lunar surface, as part of the US space agency's plan to establish a long-term human presence on the Moon by 2030.
The $14.1 million contract, awarded to Nokia's US subsidiary, is part of NASA's Artemis programme which aims to send the first woman, and next man, to the moon by 2024.
The astronauts will begin carrying out detailed experiments and explorations which the agency hopes will help it develop its first human mission to Mars.
Nokia's network equipment will be installed remotely on the Moon's surface using a lunar hopper built by Intuitive Machines in late 2022, Nokia said.
"The network will self-configure upon deployment," the firm said in a statement, adding that the wireless technology will allow for "vital command and control functions, remote control of lunar rovers, real-time navigation and streaming of high definition video."
The 4G equipment can be updated to a super-fast 5G network in the future, Nokia said.
In all, NASA announced last week it would distribute $370 million to 14 companies to supply "Tipping Point" technologies for its mission, which include robotics and new methods of harvesting the resources required for living on the moon, such as oxygen and energy sources.
The bulk of the funding went to companies researching cryogenic propellants, freezing liquids used to fuel spacecraft.
Among them, Elon Musk's SpaceX received $53.2 million for a demonstration of the transferring of ten metric tons of liquid oxygen between tanks on a starship vehicle, NASA said.
from Firstpost Tech Latest News https://ift.tt/2JgFz25
Taapsee Pannu introduces her character Rani Kashyap as she wraps up Haseen Dilruba
from IndiaTV Entertainment: Google News Feed https://ift.tt/3mBTDli
Deepa Mehta's 'Funny Boy' chosen as Canada's submission for international film Oscar
from IndiaTV Entertainment: Google News Feed https://ift.tt/3ed5p2C
World Psoriasis Day 2020: Timely Diagnosis and Correct Treatment are Crucial for This Disease
from Top Lifestyle News- News18.com https://ift.tt/2TEaVS9
Treat nature right or future pandemics will wreck more havoc than COVID-19 did says UN panel
Future pandemics will happen more often, kill more people and wreak even worse damage to the global economy than Covid-19 without a fundamental shift in how humans treat nature, the United Nations' biodiversity panel said Thursday.
Warning that there are up to 850,000 viruses which, like the novel coronavirus, exist in animals and may be able to infect people, the panel known as IPBES said pandemics represented an "existential threat" to humanity.
Authors of the special report on biodiversity and pandemics said that habitat destruction and insatiable consumption made animal-borne diseases far more likely to make the jump to people in future.
"There is no great mystery about the cause of the Covid-19 pandemic — or any modern pandemic," said Peter Daszak, president of the Ecohealth Alliance and chair of the IPBES workshop that drafted the report.
"The same human activities that drive climate change and biodiversity loss also drive pandemic risk though their impacts on our agriculture."
The panel said that Covid-19 was the sixth pandemic since the influenza outbreak of 1918 —all of which had been "entirely driven by human activities".
These include unsustainable exploitation of the environment through deforestation, agricultural expansion, wildlife trade and consumption — all of which put humans in increasingly close contact with wild and farmed animals and the diseases they harbour.
Seventy percent of emerging diseases — such as Ebola, Zika and HIV/AIDS — are zoonotic in origin, meaning they circulate in animals before jumping to humans.
Around five new diseases break out among humans every single year, any one of which has the potential to become a pandemic, the panel warned.
Land use
IPBES said in its periodic assessment on the state of nature last year that more than three-quarters of land on Earth had already been severely degraded by human activity.
One-third of land surface and three-quarters of freshwater on the planet is currently taken up by farming, and humanity's resource use has rocketed up 80 percent in just three decades, it said.
IPBES conducted a virtual workshop with 22 leading experts to come up with a list of options that governments could take to lower the risk of repeat pandemics.
It acknowledged the difficulty in counting the full economic cost of Covid-19.
But the assessment pointed to estimated costs as high as $16 trillion as of July 2020.
The experts said that the cost of preventing future pandemics was likely to be 100 times cheaper than responding to them, "providing strong economic incentives for transformative change".
"Our approach has effectively stagnated," Daszak said.
"We still rely on attempts to contain and control diseases after they emerge, through vaccines and therapeutics."
Withering reminder
The IPBES suggested a global, coordinated pandemic response, and for countries to agree upon targets to prevent biodiversity loss within an international accord similar to the Paris agreement on climate change.
Among the options for policymakers to reduce the likelihood of a Covid-19 re-run are taxes or levies on meat consumption, livestock production and other forms of "high pandemic-risk activities".
The assessment also suggested better regulation of international wildlife trade and empowering indigenous communities to better preserve wild habitats.
Nick Ostle, a researcher at the CEH Lancaster Environment Centre, Lancaster University, said the IPBES' assessment should serve as a "withering reminder" of how reliant humanity is on nature.
"Our health, wealth and wellbeing relies on the health, wealth and wellbeing of our environment," said Ostle, who was not involved in the research process.
"The challenges of this pandemic have highlighted the importance of protecting and restoring our globally important and shared environmental 'life-support' systems."
from Firstpost Tech Latest News https://ift.tt/2Jk4wd7
Eight-nation space coalition banded together under 'Artemis Accords' by NASA
Eight nations have signed on to become founding members of NASA's Artemis Accords, an international agreement that establishes how countries can cooperate to peacefully and responsibly conduct exploration of the moon.
NASA announced Tuesday that the United States signed the accords, together with Australia, Canada, Italy, Japan, Luxembourg, the United Arab Emirates and the United Kingdom. NASA Administrator Jim Bridenstine said the agreement would establish a “singular global coalition” to guide future expeditions to the moon.
“With today’s signing, we are uniting with our partners to explore the moon and are establishing vital principles that will create a safe, peaceful and prosperous future in space for all of humanity to enjoy,” Bridenstine said in a statement released Tuesday.
NASA developed the Artemis Accords to partner with other nations to set basic principles to guide robotic and crewed lunar exploration. The agreement’s name refers to NASA’s Artemis program, which aims to send astronauts, including the first woman, to the moon by 2024.
The accords include provisions for peaceful exploration, safety, transparency, sustainable use of space resources, cooperation to build and operate spacecraft and other hardware, and the management and disposal of orbital debris.
“Fundamentally, the Artemis Accords will help to avoid conflict in space and on Earth by strengthening mutual understanding and reducing misperceptions,” Mike Gold, NASA’s acting associate administrator for international and interagency relations, said in a statement. “The Artemis journey is to the moon, but the destination of the Accords is a peaceful and prosperous future.”
The Artemis Accords build on another major international agreement known as the Outer Space Treaty, which was enacted in 1967. The Outer Space Treaty bans the use of nuclear weapons or any other weapons of mass destruction in space and establishes that exploration of space, the moon and other celestial bodies should only be for peaceful purposes.
from Firstpost Tech Latest News https://ift.tt/3mBlwd2
Blue Origin successfully tests its New Shepard rocket for space tourism flights
Blue Origin, the US space company founded by billionaire Jeff Bezos, succeeded Tuesday in its latest test flight of its rocket aimed at one day taking tourists to space, even as the date of the first crewed launch remains unclear.
The New Shepard capsule, which was propelled over the boundary of space by a small reusable launch vehicle that returned to land vertically, will one day carry up to six passengers.
It attained an altitude of 66 miles (106 kilometers) above sea level, before descending back to the surface using parachutes and landing in a cloud of dust in the desert of West Texas.
Its total flight time was 10 minutes and nine seconds.
Blue Origin previously unveiled the capsule's interior: six seats with horizontal backrests, placed next to large portholes, in a futuristic cabin with swish lighting.
Multiple cameras help immortalize the few minutes the tourists experience weightlessness while taking in the Earth's curvature.
This summer, competitor Virgin Galactic showed off the interior of its own vessel which is one day supposed to take private passengers to the boundaries of space for a few minutes.
But neither company has announced the start of commercial flights, which have been expected for years.
from Firstpost Tech Latest News https://ift.tt/2TBCWd9
Suhana Khan's quirky birthday wish for Ananya Panday; asks to teach her way of never being rejected| Video
from IndiaTV Entertainment: Google News Feed https://ift.tt/34CmVKm
Sanjana Sanghi pens emotional note as Fault in Our Stars author John Green praises her in Dil Bechara
from IndiaTV Entertainment: Google News Feed https://ift.tt/3mEVzt1
World Psoriasis Day 2020: Timely Diagnosis and Correct Treatment are Crucial for This Disease
from Top Lifestyle News- News18.com https://ift.tt/2TEaVS9
Amazon, Apple, Facebook, other big tech bounce back sooner, stronger than the economy
While the rest of the U.S. economy languished earlier this year, the tech industry’s biggest companies seemed immune to the downturn, surging as the country worked, learned and shopped from home. On Thursday, as the economy is showing signs of improvement, Amazon, Apple, Alphabet and Facebook reported profits that highlighted how a recovery may provide another catalyst to help them generate a level of wealth that hasn’t been seen in a single industry in generations.
With an entrenched audience of users and the financial resources to press their leads in areas like cloud computing, e-commerce and digital advertising, the companies demonstrated again that economic malaise, upstart competitors and feisty antitrust regulators have had little effect on their bottom line.
Combined, the four companies reported a quarterly net profit of $38 billion.
Amazon reported record sales, and an almost 200% rise in profits, as the pandemic accelerated the transition to online shopping. Despite a boycott of its advertising over the summer, Facebook had another blockbuster quarter. Alphabet’s record quarterly net profit was up 59%, as marketers plowed money into advertisements for Google search and YouTube. And Apple’s sales rose even though the pandemic forced it to push back the iPhone 12’s release to October, in the current quarter.
On Tuesday, Microsoft, Amazon’s closest competitor in cloud computing, also reported its most profitable quarter, growing 30% from a year earlier.
“The scene that’s playing out fundamentally is that these tech stalwarts are gaining more market share by the day,” said Dan Ives, managing director of equity research at Wedbush Securities. “It’s ‘A Tale of Two Cities’ for this group of tech companies and everyone else.”
The results were strong despite increasing antitrust scrutiny from regulators. Last week, the Justice Department filed a lawsuit accusing Google of cementing the dominance of its search engine through anti-competitive agreements with device makers and mobile carriers. Facebook faces a possible antitrust case from the Federal Trade Commission.
The companies’ advantages are becoming more pronounced in an economy starting to dig out from the coronavirus pandemic. On Thursday, the Commerce Department said U.S. economic output grew 7.4% last quarter, the fastest pace on record, but remained below where it was in the last pre-pandemic quarter.
That slow return to health is also providing momentum to companies that suffered early in the pandemic, like Twitter, which reported on Thursday that revenue rose 14% in the third quarter as advertisers started to return. Twitter’s stock dropped about 14% in after-hours trading on Thursday, a reaction that analysts attributed to slow user growth.
Big Tech’s third-quarter boom could look modest when compared with the final quarter of the year. For Apple, it’s when consumers buy newly released iPhones. And the year-end shopping peak means lots of customers turning to Amazon for gifts, while advertisers rely on Google and Facebook for digital ads during the holidays.
Amazon
The pandemic-fueled surge in online shopping pushed Amazon to a record for both sales and profits in the latest quarter.
Sales were $96.1 billion, up 37% from a year earlier, and profits rose to $6.3 billion.
The quarter did not include the usual boost from Prime Day, Amazon’s yearly deal bonanza, which was delayed to October. And the profit increased during a building boom, with Amazon expanding its fulfillment infrastructure by 50% this year. The company added almost 250,000 employees in the quarter, for the first time surpassing more than 1 million workers.
The lucrative Amazon Web Services division grew 29% as companies continued their shift to cloud computing.
Amazon said sales could reach $121 billion in the fourth quarter because of the confluence of Prime Day, the holiday shopping season and the turn to online spending.
Apple
The delay in the iPhone 12’s release meant Apple would face a tough comparison with the same quarter last year, which included sales of the iPhone 11. As a result, iPhone sales dropped more than 20% in the quarter.
Yet Apple’s overall sales still rose 1% to $64.7 billion, showing the increasing strength of other parts of the company’s business.
Apple’s services segment, which includes revenues from the App Store and offerings like Apple Music, increased 16% to $14.5 billion. Sales rose 46% for iPads, 29% for Mac computers and 21% for wearables.
Profits fell 7% to $12.7 billion, partly because the company spent more on research and development.
“There are lots going on here, and everything is going incredibly well,” Luca Maestri, Apple’s finance chief, said in an interview.
Facebook’s revenue for the third quarter rose 22% from a year earlier, to $21.2 billion, while profits jumped 29% to $7.84 billion. The results surpassed analysts’ estimates of $19.8 billion in revenue and profits of $5.53 billion, according to data provided by FactSet.
Facebook had strong results despite a wide-ranging boycott by advertisers this summer over issues of hate and toxic speech on the site. Although the grassroots campaign, Stop Hate for Profit, rallied many of the top advertisers on Facebook to reduce their spending, the overall effects were brief.
The company continued gaining users as well. More than 1.82 billion people used the Facebook app every day, up 12% from a year earlier, it said. More than 2.54 billion people now use one or more of Facebook’s family of apps — Instagram, WhatsApp, Messenger or Facebook — daily, up 15% from a year earlier.
Alphabet
After its first-ever decline in quarterly revenue in the second quarter, Alphabet rebounded with its highest-ever profit. The strength came from across Google, with search advertising revenue growing 6% and YouTube ad spending rising 32%. Google’s cloud computing business grew 45%.
When advertisers slowed spending with Google this year as COVID-19 started to spread, Alphabet’s business took a significant hit. But as the economy has improved and businesses found their footing, advertisers have returned.
Alphabet posted a net profit of $11.25 billion in the third quarter as revenue rose 14% to $46.1 billion. Ruth Porat, Alphabet’s chief financial officer, said the improved profitability reflected efforts to cut costs during the economic downturn, including a hiring slowdown.
Daisuke Wakabayashi, Karen Weise, Jack Nicas and Mike Isaac.
from Firstpost Tech Latest News https://ift.tt/34Dbsu6
Osiris-Rex successfully collects rock, dust samples from asteroid Bennu, for the second time
NASA said Thursday its robotic spacecraft Osiris-Rex was able to stow a rock and dust sample scooped up from the asteroid Bennu, after a flap that had wedged open put the mission at risk.
"We are here to announce today that we've successfully completed that operation," said Rich Burns, the mission's project manager.
The probe is on a mission to collect fragments that scientists hope will help unravel the origins of our solar system, but hit a snag after it picked up too big of a sample.
Fragments from the asteroid's surface in a collector at the end of the probe's three-meter (10-foot) arm had been slowly escaping into space because some rocks prevented the compartment from closing completely.
That arm is what came into contact with Bennu for a few seconds last Tuesday in the culmination of a mission launched from Earth some four years ago.
On Thursday, NASA said it had been able a day earlier to maneuver the robotic arm holding the leaking particles to a storage capsule near the center of the spacecraft, drop off the sample and close the capsule's lid.
It was a delicate two-day procedure, requiring the team at each step to assess images and data from the previous step.
The probe is 200 million miles (320 million kilometers) away, so it takes 18.5 minutes for its transmissions to reach Earth, and any signal from the control room requires the same amount of time to reach Osiris-Rex.
"My heart breaks for loss of sample," said Dante Lauretta, the mission's chief scientist, but he noted that they had successfully stowed hundreds of grams (several ounces) of fragments, far in excess of their minimum goal.
"Now we can look forward to receiving the sample here on Earth and opening up that capsule," he said.
Osiris-Rex is set to come home in September 2023, hopefully with the largest sample returned from space since the Apollo era.
from Firstpost Tech Latest News https://ift.tt/2TFOT1i
Avengers actress Scarlett Johansson gets married to Colin Jost in secret ceremony
from IndiaTV Entertainment: Google News Feed https://ift.tt/34G0cx6
Chrissy Teigen deletes posts on noticing Hillary Clinton follows her on Twitter
from IndiaTV Entertainment: Google News Feed https://ift.tt/2HLaiE0
Could COVID-19 Spread More in the Winter Season?
from Top Lifestyle News- News18.com https://ift.tt/3oEi0QW
Everything You Need to Know About Colitis, a Painful Digestive Disease
from Top Lifestyle News- News18.com https://ift.tt/3e7CXPs
Happy Birthday Abhijeet Bhattacharya: Here are His Top 5 Songs
from Top Lifestyle News- News18.com https://ift.tt/32cv32L
KBC12: What is the Rs 1 crore question that Ghaziabad's Chhavi Kumar could not answer?
from IndiaTV Entertainment: Google News Feed https://ift.tt/35OlwQa